EUVIMEDEUVIMED entdecken
CrossrefInfokarte

WWP2 Overexpression Represses NLRP3 Inflammasome Activation in Cerebral Ischemia/Reperfusion Injury Through the Degradation of MAVS

Hang Yu, Jinghao Li, Tingting Lu, Mingming Dai, Xianyao Wan

Glia · 2025-12 · 73 (12) · 2445-2463

DOI: 10.1002/glia.70077 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT NACHT, LRR, and PYD domains‐containing protein 3 (NLRP3) inflammasome plays a pivotal role in the progression of cerebral ischemia/reperfusion injury (CI/RI). We aimed to investigate the implication of WW domain‐containing protein 2 (WWP2), an E3 ubiquitin ligase, in CI/RI and its mechanism. Microglia were subjected to oxygen–glucose deprivation/reoxygenation, and mice were subjected to middle cerebral artery occlusion (MCAO) for modeling. WWP2 was reduced in the brain tissues of mice with MCAO/R. WWP2 overexpression in microglia inhibited the NLRP3 inflammasome activation to alleviate MCAO/R‐induced injury and microglia‐induced neurotoxicity. WWP2 inhibited the mitochondrial translocation of NLRP3 by degrading mitochondrial antiviral‐signaling protein (MAVS) to block its interaction with NLRP3, and MAVS overexpression in microglia promoted the NLRP3 activation to exacerbate MCAO/R and neurotoxicity. The nuclear export of TAR DNA‐binding protein 43 (TDP‐43) in MCAO/R promoted the WWP2 degradation via the (UG)n element of the 3′UTR of WWP2. TDP‐43 overexpression also impaired the blockade of NLRP3 activation and exacerbated neurotoxicity in the presence of WWP2. Overall, our investigations demonstrate that nuclear export of TDP‐43 in microglia activates NLRP3 inflammasome and exacerbates CI/RI by blocking MAVS degradation through (UG)n element‐mediated instability of WWP2.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →